Bid/Ask: Pfizer gains access to eczema sufferers; Ikea gets frugal in Europe
Pfizer snaps up Anacor Pharmaceuticals. The purchase will give Pfizer control of crisaborole, an experimental treatment for eczema, a skin condition that affects as many as 25 million Americans. If approved by the U.S. Food and Drug Administration, the drug could reach annual sales of $2 billion, according to Pfizer. Palo Alto-based Anacor also holds the rights to Kerydin, a treatment for toenail fungus.